Oxford Nanopore Technologies plc (LSE:ONT) shares fell 1.15% to 206.80p in the latest market screen, valuing the DNA and RNA sequencing specialist at around £2.0 billion.
The modest decline follows a dramatic recovery in the shares. Oxford Nanopore closed at around 122p on 18 August, the day before its interim results, and has since rallied by roughly 70%. Some profit-taking after such a strong move is not surprising.
The recovery has been supported by improving margins, a clearer path to profitability and new long-term targets that gave investors greater confidence in the company's strategy.
Key Highlights
Oxford Nanopore reported H1 2026 revenue of £116.7 million, up 10.5%, or 12.3% at constant currency. Clinical revenue rose 35.4% to £17.6 million, making it the fastest-growing customer segment, while biopharma grew 25%.
Gross margin expanded 400 basis points to 62.2%, and the adjusted EBITDA loss more than halved to £22.1 million. The overall loss narrowed to £48.0 million from £71.8 million.
The company set a new 2030 revenue target of more than $700 million, alongside an adjusted EBITDA margin above 15%, and reiterated guidance for EBITDA breakeven in FY27 and positive free cash flow in FY28.
About Oxford Nanopore Technologies
Oxford Nanopore (LSE:ONT) develops a new generation of molecular sensing technology based on nanopores. Its devices, including the MinION, GridION and PromethION, enable real-time DNA and RNA sequencing across research, clinical, biopharma and industrial applications.
The company is led by chief executive Francis Van Parys and is focused on expanding into regulated clinical markets.
Why Is LSE:ONT Down Today?
The 1.15% decline to 206.80p does not appear to be linked to new company news. Instead, it looks like profit-taking after a sharp rally.
Growth and life sciences stocks can be volatile, and a 70% gain in two months raises the bar for future news.
The company's shares had fallen from a January high near 173p to a July low around 96p, before staging their recent recovery, which highlights how volatile sentiment towards the stock can be.
Key Reasons Behind the Downtick
The first factor is profit-taking. The shares have recovered strongly from their July lows.
The second factor is revenue growth below expectations. First-half revenue missed management expectations due to weakness in China, where revenue fell around 16%, and the Middle East, down 14%.
Third, the company remains loss-making, and investors are watching cash burn closely.
Finally, the reliance on a $20 million non-recurring licensing payment to boost FY26 numbers may prompt caution about underlying growth.
Key Growth Catalysts
The biggest catalyst is clinical adoption, with clinical revenue growing more than 35% as the company prepares for regulated markets.
Margin improvement is another driver. Flow cell yield improvements and a new pricing model lifted gross margin.
The 2030 target implies mid-teens organic growth accelerating over time, with a longer-term ambition to build a $1 billion-plus revenue business.
The company also reduced its FY2026 adjusted operating cost growth guidance to between -2% and 0%, demonstrating disciplined cost control as it moves towards profitability.
Risks
The main risk is slower-than-expected revenue growth, particularly in China and the Middle East. Competition from larger sequencing companies is significant.
Cash burn, regulatory approvals and execution risk are additional considerations.
Revenue in the Americas grew more slowly than anticipated due to the timing of customer orders and contract wins, and further delays could affect growth.
Valuation
At 206.80p, Oxford Nanopore is valued at about £2.0 billion, a premium valuation for a loss-making company. The market is pricing in successful delivery of EBITDA breakeven and long-term growth targets.
Capital Returns
Oxford Nanopore does not pay a dividend and is investing in growth. Its path to positive free cash flow in FY28 is a key milestone.
What Investors Should Watch Next
Investors will watch for second-half revenue growth, clinical market progress and cost control. A trading update in early 2027 will show whether FY26 guidance of 16% to 20% constant-currency growth was met.
Overall, the 1.15% fall in LSE:ONT to 206.80p looks like a pause after a strong rebound. Margin progress and clinical growth support the case, but execution remains key.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...